Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia

Amprion Announces Research Collaboration With Mayo Clinic To Further Understand Rapidly Progressive Dementia

Amprion is pleased to announce a research collaboration with Mayo Clinic in Florida to investigate biomarker utility within the cerebrospinal fluid (CSF) from patients with Rapidly Progressive Dementia (RPD).

In a collaboration called “Prospective Measures of Outcome in Rapidly Progressive Dementia,” Amprion will perform the SYNTap® Biomarker Test on a mixed cohort of approximately 200 CSF samples from well-characterized, clinically diagnosed RPD patients and healthy controls. This research is expected to shed light on the role alpha-Synuclein (αS), a misfolded protein, plays in the neurodegenerative condition of RPD.

“We’re excited to participate in this scientific collaboration with Mayo Clinic in Florida to explore the biomarker influence of misfolded Synuclein associated with RPD,” Amprion CEO Russ Lebovitz, MD/Ph.D., remarks. “This study will help us gain valuable insights to advance the molecular understanding of this highly elusive, complex, and devastating neurological condition,” added Dr. Lebovitz.

This collaboration aims to define further the characterization, clinical evaluation, and underlying synucleinopathy in RPD. In doing so, we aim to improve the diagnostic strategies to serve this patient population better.

Amprion will attend AAIC in San Diego (7/31-8/4), and we look forward to connecting with medical professionals during this conference. Visit us at booth #305 for collaborative exchange.


A leader in Prion Detection Science™, Amprion innovates biomarker testing for brain diseases. Our SYNTap® Biomarker Test helps doctors diagnose Lewy Body Variant of Alzheimer’s Disease, Parkinson’s Disease, and Lewy Body Dementia. Amprion strives to accelerate precision medicine for neurodegenerative diseases through molecular testing.


Amprion has some important news we need to share with you!

To improve patient access to the SYNTap® biomarker test (CSF), Amprion is reducing the self-pay price for tests with service dates on or after July 1, 2023.

Old self-pay price: $1500.00. New self-pay price: $995.00

Effective July 1, 2023, there is a New ABN (Advanced Beneficiary Notification) form for use when ordering the SYNTap® biomarker test (CSF) for patients on Medicare. Order Process

CPT/PLA – The SYNTap® test has been issued a dedicated PLA code to be used when billing: 0393U
We have applied to be a medicare provider and will soon be able to courtesy bill Medicare for your patients.